Genitourinary Cancers

Pretreatment serum lactate dehydrogenase is a prognostic factor in poor-risk patients with renal cell carcinoma and also a predictive factor for a survival benefit from treatment with temsirolimus.

For those of us with administrative responsibilities in large urology groups, the dilemma is amplified by the fact that we are affected not only as providers of care but as employers.

A quick glance at a recent study examining the renal cell carcinoma immunotherapy AGS-003 and the FDA approval of a new noninvasive prostate health index test.

Partial nephrectomy is associated with better overall survival than radical nephrectomy in older patients with early-stage kidney cancer.

Pazopanib has demonstrated activity in a majority of patients with refractory urothelial cancer, providing the first evidence that targeted therapies might have a role in the disease.

Summaries of ongoing research underway in bladder, prostate, and renal cancer, intended to stimulate discussion about ongoing clinical trials and to promote collaboration across the urology community.

At Urological Associates of Southern Arizona, "collaboration" is not just a buzzword, it's part and parcel of the daily practice.

Research presented at ASCO 2012 demonstrated the efficacy of axitinib (Inlyta) as both a first- and second-line treatment in patients with metastatic renal cell carcinoma.

Tivozanib increased progression-free survival and objective response rate in patients with renal cell carcinoma compared with sorafenib.

In tough economic times when many medical practices have scaled back or even shut down, The Urology Group has flourished.

Dr. Raoul Concepcion, from Urology Associates, PC, Discusses Urologists Treating Cancer.

Spurred by the desire to provide the full spectrum of care to prostate cancer patients, urologists across the country have begun to integrate bone health clinics into their practices.

The implementation of electronic health records to replace paper charts in urology practices is a recent phenomenon that is picking up some serious momentum.

In the last seven years, since the introduction of the targeted therapies, remarkable progress has transpired that has transformed the therapeutic landscape for metastatic renal cell carcinoma.

Case-based discussion on sequencing prostate cancer therapies for a 72-year-old man with a metastatic adenocarcinoma with small-cell components, a PSA score of 80, and a Gleason score of 10.

Immunotherapy is maintaining its momentum in clinical development programs, with explorations under way in many tumor types, including breast and lung cancers previously considered poor candidates for such modalities.